Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology.
Patients with neutropenia lasting for more than 10d, who develop fever and pulmonary infiltrates, are at risk of treatment failure under conventional broad-spectrum antibacterial therapy. Filamentous fungi are predominant causes of failure, however, multi-resistant gram-negative rods such as Pseudomonas aeruginosa or Stenotrophomonas maltophilia may be involved. Prompt addition of mould-active systemic antifungal therapy, facilitated by early thoracic computed tomography, improves clinical outcome. Non-culture-based diagnostic procedures to detect circulating antigens such as galactomannan or 1,3-beta-d-glucan, or PCR techniques to amplify circulating fungal DNA from blood, bronchoalveolar lavage or tissue specimens, may facilitate the diagnosis of invasive pulmonary aspergillosis. CT-guided bronchoalveolar lavage is useful in order to identify causative microorganisms such as multidrug-resistant bacteria, filamentous fungi or Pneumocystis jiroveci. For pre-emptive antifungal treatment, voriconazole or liposomal amphotericin B is preferred. In patients given broad-spectrum azoles for antifungal prophylaxis, non-azole antifungals or antifungal combinations might become first choice in this setting. Antifungal treatment should be continued for at least 14 d before non-response and treatment modification are considered. Microbial isolates from blood cultures, bronchoalveolar lavage or respiratory secretions must be critically interpreted with respect to their aetiological relevance for pulmonary infiltrates.
Maschmeyer
Georg
G
Klinikum Ernst von Bergmann, Dept. of Haematology and Oncology, Charlottenstrasse 72, Potsdam D-14467, Germany. gmaschmeyer@klinikumevb.de
Beinert
Thomas
T
Buchheidt
Dieter
D
Cornely
Oliver A
OA
Einsele
Hermann
H
Heinz
Werner
W
Heussel
Claus Peter
CP
Kahl
Christoph
C
Kiehl
Michael
M
Lorenz
Joachim
J
Hof
Herbert
H
Mattiuzzi
Gloria
G
D000890:Anti-Infective Agents / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D001992:Bronchoalveolar Lavage Fluid / Q000382:microbiology; D005334:Fever / Q000150:complications / Q000188:drug therapy; D005658:Fungi / Q000302:isolation & purification*; D006801:Humans; D008172:Lung Diseases, Fungal / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology; D009369:Neoplasms / Q000150:complications; D009503:Neutropenia / Q000150:complications / Q000188:drug therapy; D016133:Polymerase Chain Reaction; D014057:Tomography, X-Ray Computed
D000890:Anti-Infective Agents; D000935:Antifungal Agents